Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1681 to 1685 of 1685 entries
Sorted by: Best Match Show Resources per page
Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges.

Journal of addiction medicine

Zweben JE, Sorensen JL, Shingle M, Blazes CK.
PMID: 33323695
J Addict Med. 2021 Nov-Dec 01;15(6):454-460. doi: 10.1097/ADM.0000000000000789.

This paper offers a review and recommendations for clinicians working with patients interested in discontinuing opioid agonist treatment. As buprenorphine/naloxone has gained widespread acceptance for opioid addiction, many treatment providers and patients have a range of hopes and expectations...

Cite
Zweben JE, Sorensen JL, Shingle M, et al. Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges. J Addict Med. 2021;15(6):454-460doi: 10.1097/ADM.0000000000000789.
Zweben, J. E., Sorensen, J. L., Shingle, M., & Blazes, C. K. (2021). Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges. Journal of addiction medicine, 15(6), 454-460. https://doi.org/10.1097/ADM.0000000000000789
Zweben, Joan E, et al. "Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges." Journal of addiction medicine vol. 15,6 (2021): 454-460. doi: https://doi.org/10.1097/ADM.0000000000000789
Zweben JE, Sorensen JL, Shingle M, Blazes CK. Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges. J Addict Med. 2021 Nov-Dec 01;15(6):454-460. doi: 10.1097/ADM.0000000000000789. PMID: 33323695.
Copy Download .nbib Format: NLM
Types of Medication-Assisted Treatment for Opioid Use Disorder in Turkey: The Perceptions of Inpatients about Treatment Success.

Psychiatry investigation

Erk MA, Firat S.
PMID: 33301668
Psychiatry Investig. 2020 Dec;17(12):1182-1190. doi: 10.30773/pi.2020.0307. Epub 2020 Dec 11.

OBJECTIVE: The aim of this study was the following. When the different dynamics of agonist or antagonist treatments considered it is assumed that the eligible treatment to the individual may be maintained with high efficacy. Thus, we aimed to...

Cite
Erk MA, Firat S. Types of Medication-Assisted Treatment for Opioid Use Disorder in Turkey: The Perceptions of Inpatients about Treatment Success. Psychiatry Investig. 2020;17(12):1182-1190doi: 10.30773/pi.2020.0307.
Erk, M. A., & Firat, S. (2020). Types of Medication-Assisted Treatment for Opioid Use Disorder in Turkey: The Perceptions of Inpatients about Treatment Success. Psychiatry investigation, 17(12), 1182-1190. https://doi.org/10.30773/pi.2020.0307
Erk, Mehmet Aykut, and Firat, Sunay. "Types of Medication-Assisted Treatment for Opioid Use Disorder in Turkey: The Perceptions of Inpatients about Treatment Success." Psychiatry investigation vol. 17,12 (2020): 1182-1190. doi: https://doi.org/10.30773/pi.2020.0307
Erk MA, Firat S. Types of Medication-Assisted Treatment for Opioid Use Disorder in Turkey: The Perceptions of Inpatients about Treatment Success. Psychiatry Investig. 2020 Dec;17(12):1182-1190. doi: 10.30773/pi.2020.0307. Epub 2020 Dec 11. PMID: 33301668; PMCID: PMC8560342.
Copy Download .nbib Format: NLM
Frequently asked questions about naloxone: Part 1.

Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC

Cid A, Patten A, Grindrod K, Beazely MA.
PMID: 34484479
Can Pharm J (Ott). 2021 Aug 16;154(5):301-304. doi: 10.1177/17151635211034528. eCollection 2021.

No abstract available.

Cite
Cid A, Patten A, Grindrod K, et al. Frequently asked questions about naloxone: Part 1. Can Pharm J (Ott). 2021;154(5):301-304doi: 10.1177/17151635211034528.
Cid, A., Patten, A., Grindrod, K., & Beazely, M. A. (2021). Frequently asked questions about naloxone: Part 1. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC, 154(5), 301-304. https://doi.org/10.1177/17151635211034528
Cid, Ashley, et al. "Frequently asked questions about naloxone: Part 1." Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC vol. 154,5 (2021): 301-304. doi: https://doi.org/10.1177/17151635211034528
Cid A, Patten A, Grindrod K, Beazely MA. Frequently asked questions about naloxone: Part 1. Can Pharm J (Ott). 2021 Aug 16;154(5):301-304. doi: 10.1177/17151635211034528. eCollection 2021. PMID: 34484479; PMCID: PMC8408911.
Copy Download .nbib Format: NLM
Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer's Disease.

Frontiers in pharmacology

Caruso G, Grasso M, Fidilio A, Torrisi SA, Musso N, Geraci F, Tropea MR, Privitera A, Tascedda F, Puzzo D, Salomone S, Drago F, Leggio GM, Caraci F.
PMID: 35002742
Front Pharmacol. 2021 Dec 24;12:809541. doi: 10.3389/fphar.2021.809541. eCollection 2021.

Depression is a risk factor for the development of Alzheimer's disease (AD). A neurobiological and clinical continuum exists between AD and depression, with neuroinflammation and oxidative stress being involved in both diseases. Second-generation antidepressants, in particular selective serotonin reuptake...

Cite
Caruso G, Grasso M, Fidilio A, et al. Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer's Disease. Front Pharmacol. 2021;12:809541doi: 10.3389/fphar.2021.809541.
Caruso, G., Grasso, M., Fidilio, A., Torrisi, S. A., Musso, N., Geraci, F., Tropea, M. R., Privitera, A., Tascedda, F., Puzzo, D., Salomone, S., Drago, F., Leggio, G. M., & Caraci, F. (2021). Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer's Disease. Frontiers in pharmacology, 12809541. https://doi.org/10.3389/fphar.2021.809541
Caruso, Giuseppe, et al. "Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer's Disease." Frontiers in pharmacology vol. 12 (2021): 809541. doi: https://doi.org/10.3389/fphar.2021.809541
Caruso G, Grasso M, Fidilio A, Torrisi SA, Musso N, Geraci F, Tropea MR, Privitera A, Tascedda F, Puzzo D, Salomone S, Drago F, Leggio GM, Caraci F. Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer's Disease. Front Pharmacol. 2021 Dec 24;12:809541. doi: 10.3389/fphar.2021.809541. eCollection 2021. PMID: 35002742; PMCID: PMC8740153.
Copy Download .nbib Format: NLM
Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

The International journal on drug policy

Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L.
PMID: 34736130
Int J Drug Policy. 2021 Nov 01;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub 2021 Nov 01.

BACKGROUND: Opioid agonist treatment (OAT) is an effective intervention for opioid dependence. Extended-release buprenorphine injections (BUP-XR) may have additional potential benefits over sublingual buprenorphine. This single-arm trial evaluated outcomes among people receiving 48 weeks of BUP-XR in diverse community...

Cite
Farrell M, Shahbazi J, Byrne M, et al. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Int J Drug Policy. 2021;100:103492doi: 10.1016/j.drugpo.2021.103492.
Farrell, M., Shahbazi, J., Byrne, M., Grebely, J., Lintzeris, N., Chambers, M., Larance, B., Ali, R., Nielsen, S., Dunlop, A., Dore, G. J., McDonough, M., Montebello, M., Nicholas, T., Weiss, R., Rodgers, C., Cook, J., Degenhardt, L. (2021). Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. The International journal on drug policy, 100103492. https://doi.org/10.1016/j.drugpo.2021.103492
Farrell, Michael, et al. "Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence." The International journal on drug policy vol. 100 (2021): 103492. doi: https://doi.org/10.1016/j.drugpo.2021.103492
Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Int J Drug Policy. 2021 Nov 01;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub 2021 Nov 01. PMID: 34736130.
Copy Download .nbib Format: NLM
Showing 1681 to 1685 of 1685 entries